Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. SPY
3. ANT
4. FFAI
5. FFR
6. META
7. LLY
8. TSLA
9. FICO
10. CART

Go back to Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss

Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 10, 2022 4:01 PM EDT

SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update. Recent highlights include:

Finance Update

Q1 revenues of $4.5 million; $2.2 million of revenue was attributable to the license agreement with Emergent BioSolutions, Inc. (EBS) for the sale of NARCAN® Nasal Spray

The royalty rate reduced in Q1 due to EBS applying the Generic... More